Skip to main content

Prescription Drug Price Transparency Rulemaking Advisory Committee (HB 4005)

The Department of Consumer and Business Services (DCBS) convened an advisory committee to establish the 2018 Prescription Drug Price Transparency Act to provide notice and disclosure of information relating to the cost and pricing of prescription drugs in order to provide accountability for prescription drug pricing. The results of the committee's work are now awaiting a rulemaking hearing to be adopted into law.

Meetings and documents

Public comments received

Committee members

Notice of proposed rulemaking

January 22, 2019, 10:00 a.m.
Last day for public comment: February 1, 2019, 5 p.m.


Committee contact

Jesse O'Brien
Senior Policy Analyst
Oregon Division of Financial Regulation
Phone: (971) 707-3670


Your browser is out-of-date! It has known security flaws and may not display all features of this and other websites. Learn how